Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 075 IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 075 IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride is a potassium supplement that replaces intracellular potassium, maintaining cellular membrane potential, acid-base balance, and nerve conduction. Sodium chloride provides isotonicity and replaces sodium and chloride ions.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion: Potassium chloride 0.075% (7.5 mEq/L) in sodium chloride 0.9% at a rate of 100-200 mL/hour (0.75-1.5 mEq K+/hour). Typical adult dose: 7.5-15 mEq potassium per day via continuous infusion.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
No true elimination half-life in classic sense; potassium is rapidly distributed and eliminated via renal excretion with a functional half-life of approximately 8-12 hours in patients with normal renal function.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Primarily renal (>90% excreted unchanged in urine); minimal fecal/biliary elimination.
Category C
Category A/B
Electrolyte
Electrolyte